DCM
TXMD icon

Dupont Capital Management’s TherapeuticsMD TXMD Stock Holding History

Dupont Capital Management’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,127
Closed -$370K – 1225
2018
Q3 		$370K Hold
1,127
– – 0.01% 781
2018
Q2 		$352K Buy
+1,127
New +$344K 0.01% 791

Other funds holding TXMD

Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Dupont Capital Management's TXMD Position: Q4 2018 in Review

Dupont Capital Management sold out of TherapeuticsMD (TXMD) in Q4 2018, closing a stake of 1,127 shares — an estimated $370K sold.

Dupont Capital Management first reported a position in TXMD in Q2 2018 and held it in 2 quarters. The position peaked at $370K in Q3 2018. 140 funds tracked by Wall St. Rank hold TXMD as of Q4 2018.

  • Dupont Capital Management reported no remaining TherapeuticsMD position as of Q4 2018 after selling out during the quarter.
  • Dupont Capital Management sold 1,127 TherapeuticsMD shares in Q4 2018, an estimated $370K.
  • Dupont Capital Management first reported a position in TherapeuticsMD in Q2 2018 and held it in 2 quarters.
  • Dupont Capital Management's TherapeuticsMD position peaked at $370K in Q3 2018.
  • 140 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2018.

Based on Dupont Capital Management's 13F filing for Q4 2018, filed 1 Feb 2019.